Vanderbilt Food Allergy Clinical Research Center
Vanderbilt University Medical Center (VUMC) CoFAR Clinical Research Center
This project will compare two ways of giving small amounts of peanut to infants at risk for peanut allergy while building a center to study and improve care for food allergies, including alpha-gal syndrome.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11325736 on NIH RePORTER |
What this research studies
At Vanderbilt we are creating a clinical research center to run high-quality trials and studies focused on preventing and managing food allergies. One main trial will compare a low once-weekly peanut dose (2 g) to the standard thrice-weekly dosing (total 6 g per week) in infants at risk for peanut allergy. The center will also run multi-site studies and laboratory work to learn more about causes of food allergy, including the tick-related alpha-gal syndrome, and will support newer investigators to speed progress. Families would come to Vanderbilt or participating CoFAR sites for visits, sample collection, and follow-up.
Who could benefit from this research
Good fit: Ideal candidates include infants at increased risk for developing peanut allergy for the prevention trial, and people of any age with suspected or diagnosed food allergy including alpha-gal syndrome for related studies.
Not a fit: People without food allergy concerns or those with established severe peanut allergy seeking immediate treatment are unlikely to benefit directly from the prevention trial.
Why it matters
Potential benefit: If successful, this work could make peanut allergy prevention easier to follow and improve diagnosis and care for people with food allergies including alpha-gal syndrome.
How similar studies have performed: Previous early-introduction trials (for example LEAP) showed that regular peanut exposure can prevent peanut allergy, but dosing schedules like those tested here are still being refined.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Bacharier, Leonard B — Vanderbilt University Medical Center
- Study coordinator: Bacharier, Leonard B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.